Description
DRUG: MELPHALAN HCL, 50MG VIAL FOR INJECTION, 10ML
First action · last action
2016-06-22 · 2016-06-22
Transactions
1
First transaction's obligation
$112,285
Base + all options value (sum of deltas)
$112,285
Extent competed
NOT COMPETED
Other than full & open authority
URGENCY
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2016-06-22+$112,285= $112,285
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2016-06-22 | +$112,285 | $112,285 | DRUG: MELPHALAN HCL, 50MG VIAL FOR INJECTION, 10ML |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI JTAPCFM4NSL4)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26024P0343 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $10,312 | FY2024 |
| 36C24824P0748 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $56,559 | FY2024 |
| 36C25724P0104 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6505 · DRUGS AND BIOLOGICALS | $41,571 | FY2024 |
| 36C24724P0133 | 247-NETWORK CONTRACT OFFICE 7 (36C247) · 6505 · DRUGS AND BIOLOGICALS | $10,393 | FY2024 |
| 36C24824P0161 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $27,010 | FY2024 |
| 36C24823P2639 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $31,862 | FY2023 |
Other recipients under 6810 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26018P3900 | LIFE CHEMICALS INC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $80,976 | FY2018 |
| VA26018P2530 | BSE PERFORMANCE, LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $24,960 | FY2018 |
| VA26017F0129 | UNITED THERAPEUTICS CORP | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $91,147 | FY2017 |
| VA26017J3080 | ARIAD PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $79,221 | FY2017 |
| VA26016F1444 | LUNDBECK LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $6,829 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26016P1112_3600_-NONE-_-NONE- · retrieved 2026-09-26.